Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 6, 2005, Pages 664-674

  Aarnoutse, Rob E ^a   Kleinnijenhuis, Johanneke ^b   Koopmans, Peter P ^b   Touw, Daan J ^b   Wieling, Jaap ^b   Hekster, Yechiel A ^b   Burger, David M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; RITONAVIR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; HUMAN; LOW DRUG DOSE; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; URINARY TRACT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DESIPRAMINE; DEXTROMETHORPHAN; DEXTRORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HETEROZYGOTE; HIV PROTEASE INHIBITORS; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; RITONAVIR; TIME FACTORS;

EID: 28844482323     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.09.001     Document Type: Article

References (36)

1. M.M. De Maat, G.C. Ekhart, A.D. Huitema, C.H. Koks, J.W. Mulder, J.H. Beijnen Drug interactions between antiretroviral drugs and comedicated agents Clin Pharmacokinet 42 2003 223 282
2. A. Hsu, G.R. Granneman, R.J. Bertz Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents Clin Pharmacokinet 35 1998 275 291
3. R. Bertz, G. Cao, J.H. Cavanaugh, A. Hsu, G.R. Granneman, J.M. Leonard Effect of ritonavir on the pharmacokinetics of desipramine [abstract MoB1201] Proceedings of the Eleventh International AIDS Conference; 1996 Jul 7-12; Vancouver, British Columbia, Canada 1996 The Conference Vancouver
4. G.J. Moyle, D. Back Principles and practice of HIV-protease inhibitor pharmacoenhancement HIV Med 2 2001 105 113
5. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. April 7, 2005. Available from: URL: www.aidsinfo.nih.gov/ guidelines. Accessed June 6, 2005.
6. F.R. Sallee, B.G. Pollock Clinical pharmacokinetics of imipramine and desipramine Clin Pharmacokinet 18 1990 346 364
7. D.J. Touw Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes Drug Metabol Drug Interact 14 1997 55 82
8. L.W. Yun, M. Maravi, J.S. Kobayashi, P.L. Barton, A.J. Davidson Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients J Acquir Immune Defic Syndr 38 2005 432 438
9. S.R. Penzak, Y.S. Reddy, S.R. Grimsley Depression in patients with HIV infection Am J Health Syst Pharm 57 2000 376 386
10. M.R. DiMatteo, H.S. Lepper, T.W. Croghan Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence Arch Intern Med 160 2000 2101 2107
11. B. Schmid, J. Bircher, R. Preisig, A. Kupfer Polymorphic dextromethorphan metabolism co-segregation of oxidative O-demethylation with debrisoquin hydroxylation Clin Pharmacol Ther 38 1985 618 624
12. J. Urquhart The electronic medication event monitor lessons for pharmacotherapy Clin Pharmacokinet 32 1997 345 356
13. W.J. Tamminga, J. Wemer, B. Oosterhuis, R.A. de Zeeuw, L.F. de Leij, J.H. Jonkman The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers Eur J Clin Pharmacol 57 2001 717 722
14. J. Wieling, W.J. Tamminga, E.P. Sakiman, B. Oosterhuis, J. Wemer, J.H. Jonkman Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening Ther Drug Monit 22 2000 486 496
15. J.A.H. Droste, C.P.W.G.M. Verweij-van Wissen, D.M. Burger Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography Ther Drug Monit 25 2003 393 399
16. D.L. Kurtz, R.F. Bergstrom, M.J. Goldberg, B.J. Cerimele The effect of sertraline on the pharmacokinetics of desipramine and imipramine Clin Pharmacol Ther 62 1997 145 156
17. S. Madani, D. Barilla, J. Cramer, Y. Wang, C. Paul Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers J Clin Pharmacol 42 2002 1211 1218
18. L.L. Von Moltke, D.J. Greenblatt, M.M. Cotreau-Bibbo, S.X. Duan, J.S. Harmatz, R.I. Shader Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole a model system to predict drug interactions in vivo J Pharmacol Exp Ther 268 1994 1278 1283
19. L.L. Von Moltke, D.J. Greenblatt, S.X. Duan, J.P. Daily, J.S. Harmatz, R.I. Shader Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors relation to drug interactions in vivo J Pharm Sci 87 1998 1184 1189
20. M.H. Skinner, H.Y. Kuan, A. Pan, K. Sathirakul, M.P. Knadler, C.R. Gonzales Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers Clin Pharmacol Ther 73 2003 170 177
21. R. Bertz, C. Foit, Y.-L. Chiu, B. Bernstein, S. Boller, J.R. Owen Multiple-dose Kaletra (lopinavir/ritonavir) does not affect the pharmacokinetics of the CYP2D6 probe, desipramine [abstract 433-W] Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle, Washington 2002 The Conference Seattle
22. M. Somer, J. Kallio, U. Pesonen, K. Pyykko, R. Huupponen, M. Scheinin Influence of hydroxychloroquine on the bioavailability of oral metoprolol Br J Clin Pharmacol 49 2000 549 554
23. A.D. Kashuba, A.N. Nafziger, G.L. Kearns, J.S. Leeder, C.S. Shirey, R. Gotschall Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping Pharmacogenetics 8 1998 403 410
24. J. Chladek, G. Zimova, J. Martinkova, I. Tuma Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects Fundam Clin Pharmacol 13 1999 508 515
25. L. Labbe, C. Sirois, S. Pilote, M. Arseneault, N.M. Robitaille, J. Turgeon Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates Pharmacogenetics 10 2000 425 438
26. J.S. McCune, C. Lindley, J.L. Decker, K.M. Williamson, A.M. Meadowcroft, D. Graff Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan J Clin Pharmacol 41 2001 723 731
27. D.R. Jones, J.C. Gorski, B.D. Haehner, E.M. O'Mara Jr, S.D. Hall Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation Clin Pharmacol Ther 60 1996 374 384
28. J. Ducharme, S. Abdullah, I.W. Wainer Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity J Chromatogr B Biomed Appl 678 1996 113 128
29. M.A. Bruce, S.D. Hall, B.D. Haehner-Daniels, J.C. Gorski In vivo effect of clarithromycin on multiple cytochrome P450s Drug Metab Dispos 29 2001 1023 1028
30. W.M. Cai, B. Chen, Y. Zhou, Y.D. Zhang Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers Clin Pharmacol Ther 66 1999 516 521
31. A.D. Kashuba, A.N. Nafziger, G.L. Kearns, J.S. Leeder, R. Gotschall, M.L. Rocci Jr Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping Clin Pharmacol Ther 64 1998 257 268
32. W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Weiling, B. Wilffert, L.F. de Leij CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers indications for oral contraceptive-related gender differences Eur J Clin Pharmacol 55 1999 177 184
33. S. Hagg, O. Spigset, R. Dahlqvist Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers Br J Clin Pharmacol 51 2001 169 173
34. E. Steiner, E. Spina Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators Clin Pharmacol Ther 42 1987 278 282
35. B.A. Hamelin, A. Bouayad, J. Methot, J. Jobin, P. Desgagnes, P. Poirier Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity Clin Pharmacol Ther 67 2000 466 477
36. J.B. Guiard-Schmid, J.M. Poirier, J.L. Meynard, P. Bonnard, A.H. Gbadoe, C. Amiel High variability of plasma drug concentrations in dual protease inhibitor regimens Antimicrob Agents Chemother 47 2003 986 990